Continuous Glucose Monitoring for Type 2 Diabetes

Recruiting in Palo Alto (17 mi)

Overseen byGeorge King, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Joslin Diabetes Center

Approved in 5 Jurisdictions

Trial Summary

What is the purpose of this trial?This trial aims to see if continuous glucose monitors (CGM) are practical and beneficial for Asian Americans with Type 2 Diabetes. The study will compare CGM use with other methods to evaluate health outcomes and quality of life. Researchers will also look at social and community factors affecting CGM use. Continuous glucose monitoring (CGM) technology has become an effective complement to other blood glucose monitoring methods and has been widely applied in clinical practice since its development.

Eligibility Criteria

This trial is for Chinese Americans, 40 years or older, who are first-generation immigrants with type 2 diabetes and an HbA1c level over 7.5%. Participants must be new to using CGM, own a smartphone, and speak English or Chinese. It's not for pregnant women, prisoners, those with severe illnesses including those on dialysis, learning disabilities or dementia.

Inclusion Criteria

I am a first-generation Chinese American over 40 with Type 2 Diabetes.

Participants should also possess a smartphone, as this is needed in order to facilitate the collection of CGM data by the study team as well as homogenize CGM usage education

Your average blood sugar level, measured by HbA1c, is higher than 7.5% within 3 months before the study starts.

+1 more

Exclusion Criteria

I cannot travel because of my health condition.

I am currently receiving or planning to receive heat treatments that may not allow the use of CGM.

I have been diagnosed with a cognitive impairment or learning disability.

+4 more

Participant Groups

The study compares the effectiveness of continuous glucose monitoring (CGM) versus traditional fingerstick monitoring in managing type 2 diabetes among Asian Americans. It will evaluate usability of CGMs, impact on quality of life and health outcomes like blood sugar and cholesterol levels.

2Treatment groups

Active Control

Placebo Group

Group I: Participants on CGMActive Control1 Intervention

Participants in this group will be offered a CGM device for glucose monitoring, with training and educational materials provided in either English or Chinese, according to the participant's preference.

Group II: Participants on Finger-stick onlyPlacebo Group1 Intervention

Participants in this group continue standard fingerstick self-monitoring of blood glucose (FSGM) as per standard care protocol. They will also receive educational materials provided in either English or Chinese, according to the participant's preference.

Continuous Glucose Monitor is already approved in United States, European Union, Canada, Japan, Australia for the following indications:

🇺🇸 Approved in United States as Continuous Glucose Monitor for: